The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 11, 2024
Filed:
Jun. 05, 2019
Applicant:
Signpath Pharma, Inc., Sandy, UT (US);
Inventors:
Assignee:
Signpath Pharma Inc., Sandy, UT (US);
Primary Examiner:
Int. Cl.
CPC ...
A61B 5/00 (2006.01); A61B 5/364 (2021.01); A61K 9/00 (2006.01); A61K 9/127 (2006.01); A61K 31/12 (2006.01); A61K 31/445 (2006.01); A61K 31/4545 (2006.01); A61K 31/506 (2006.01); A61K 31/683 (2006.01);
U.S. Cl.
CPC ...
A61B 5/4848 (2013.01); A61B 5/364 (2021.01); A61K 9/0019 (2013.01); A61K 9/127 (2013.01); A61K 31/12 (2013.01); A61K 31/445 (2013.01); A61K 31/4545 (2013.01); A61K 31/506 (2013.01); A61K 31/683 (2013.01); A61B 2503/42 (2013.01);
Abstract
Compositions and methods are provided for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns, or both, in a human or animal subject comprising: one or more pharmacologically active agents that causes at least one of Ichannel inhibition or QT prolongation by inhibiting the activity of an ether-a-go-go-related gene (hERG); and one or more liposomes, wherein the liposomes are empty liposomes and administered prior to, concomitantly, or after administration of the pharmacologically active agent.